Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials.
about
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trialsOptogenetic control of contractile function in skeletal muscleInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Progress and prospects of gene therapy clinical trials for the muscular dystrophies.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.Signs of progress in gene therapy for muscular dystrophy also warrant cautionSuccessful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies.Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9.Gene Therapy for Duchenne muscular dystrophy.Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.CpG-depleted adeno-associated virus vectors evade immune detection.Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways.Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.Gene therapy research at the frontiers of viral immunology.Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.
P2860
Q26741409-D8D2E92A-AD83-4255-B641-3969B0778C55Q30655090-DCE0E457-3821-47B7-BB45-AD0D4B22E2F0Q33736192-EA3389ED-39B4-4453-BFB5-6D9454D966F4Q33902499-781A9C28-FA3D-4C79-A0DC-D961D8678E8BQ34497471-F293F37D-A86B-409E-81E0-C3F1228F07E0Q34566454-7A1149F0-AFB5-4A04-8874-CFA85682AE9BQ34814931-493E90D5-4725-4002-B93D-6F93C4B6F43AQ35750023-F1EFDC42-BF1B-4A55-A57A-AF22EEAEF58DQ36142496-1E857125-A829-4462-A5CE-669D8ACB50D8Q36270357-DC68A194-4204-4BEF-8B3C-31A2CF52F10EQ36295934-B50F4E02-0619-4EBD-9C8D-4953E1BAA233Q36582796-AAB5CABE-F17E-4DFA-B565-CBB65DD8F855Q36966955-9822696C-80AB-480B-A747-300FE786671CQ37686976-1F4DE630-CCC0-4D08-9CEA-52E1E0B92684Q38195598-4994BEA7-E813-4DDC-A5AC-8FA479928822Q38257312-83B8B103-90C4-41C9-9DB5-C8F36B36D8E6Q38539938-7AC064A1-7D8A-40DA-9E0D-A499CE3D9917Q40928395-681CBBDA-2B9B-49A4-9738-51EFAFDAAD02Q41136552-47C76E66-5D5E-4910-B6F7-9F67847534B9Q42227245-4C5CF74F-97F1-49F7-9385-FC8177E7BB31Q47345657-A7C2B515-D702-4FDA-88B8-ABD9021F10AC
P2860
Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@en
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@nl
type
label
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@en
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@nl
prefLabel
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@en
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@nl
P2093
P2860
P356
P1476
Immunity and AAV-Mediated Gene ...... nimal Models and Human Trials.
@en
P2093
Jeffrey S Chamberlain
Stephen J Tapscott
Zejing Wang
P2860
P356
10.3389/FMICB.2011.00201
P577
2011-09-26T00:00:00Z